GlassScriptPhysician profile
Laureta Sey
NPI 1639812332
$4,777.11
in general payments reported to CMS, 2019-2025
26 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.43 · 2023: $1,263 · 2024: $2,246 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,012.67 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $786.21 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $422.53 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $349.84 | 2024-2025 | |
| Exact Sciences Corporation | $320.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $286.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $259.67 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $259.18 | 2023-2025 | Veozah, Vesicare |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.22 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $149.09 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $119.57 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $84.08 | 2024-2025 | Capvaxive |
| Sumitomo Pharma America, INC. | $74.29 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $73.71 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $72.32 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $66.85 | 2025 | Zoryve |
| Amgen INC. | $41.99 | 2024 | Krystexxa |
| Eisai INC. | $34.07 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.61 | 2024 | Vpriv |
| Axsome Therapeutics, INC. | $23.69 | 2025 | Symbravo |
| Dexcom, INC. | $23.43 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $22.73 | 2023 | |
| Horizon Therapeutics Plc | $21.33 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $19.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.24 | 2023 | Airduo Digihaler |
| Antares Pharma, INC. | $16.02 | 2024 | Xyosted, Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laureta Sey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.